Century Therapeutics, Inc. (IPSC) Misses Q4 EPS by 168c

Century Therapeutics, Inc. (NASDAQ: IPSC) reported Q4 EPS of ($2.27), $1.68 worse than the analyst estimate of ($0.59). Revenue for the quarter came in at $5.2 million versus the consensus estimate of $2.27 million.

For earnings history and earnings-related data on Century Therapeutics, Inc. (IPSC) click here.

You May Also Be Interested In

• Solstice acquiring Element Solutions in $14.5B cash and stock deal
• Radoff-Jumana Group calls for Genesco CEO to lose board chair role
• Volato Group reports Q2 2026 preliminary results with Vaunt growth